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Abstract
The Nuclear factor-E2 related factor 2 (Nrf2)-Kelch-like ECH-associated protein 1 (Keap1)
pathway upregulates antioxidant and biotransformation enzyme expression to counter cellular
oxidative stress. The contribution of Nrf2 to other cellular functions, such as lipid homeostasis is
emerging. The present study was conducted to determine how enhanced Nrf2 activity impacts
progression of metabolic syndrome with long-term high fat diet (HFD) feeding. C57BL/6 and
Keap1-Knockdown (Keap1-KD) mice, which exhibit enhanced Nrf2 activity, were fed a HFD for
24 weeks. Keap1-KD mice had higher body weight and white adipose tissue mass compared to
C57BL/6 mice on HFD, along with increased inflammation and lipogenic gene expression. HFD
feeding increased hepatic steatosis and inflammation to a greater extent in Keap1-KD mice
compared to C57BL/6 mice, which was associated with increased liver Cd36, fatty acid binding
protein 4 (Fabp4), and monocyte chemoattractant protein 1 (Mcp1) mRNA expression, as well as,
increased acetyl CoA carboxylase 1 (Acc1) and Steroyl CoA desaturase 1 (Scd1) protein
expression. The HFD altered short-term glucose homeostasis to a greater degree in Keap-KD mice
compared to C57BL/6 mice, which was accompanied by down regulation of Insulin receptor
substrate 1 mRNA expression in skeletal muscle. Together, the results indicate that Keap1
knockdown, on treatment with HFD, increases certain markers of metabolic syndrome.
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INTRODUCTION
Metabolic syndrome is described as a cluster of risk factors that increase risk for developing
cardiovascular disease [1]. Some of the risk factors include central obesity, atherogenic
dyslipidemia (elevated triglycerides and low HDL cholesterol), insulin resistance (with or
without glucose intolerance), and a proinflammatory state. In 2003-2009, in an analytic
sample that consisted of 3,423 adults, 20 years of age and over, 34% of American adults met
the criteria for metabolic syndrome [2].
Nuclear factor E2 related factor 2 (Nrf2) is a basic leucine zipper transcription factor, which
regulates basal and inducible expression of multiple antioxidant and biotransformation genes
[3]. Kelch-like ECH-associated protein 1 (Keap1) is a cysteine rich protein that binds Nrf2
in the cytosol, and is a critical determinant for Nrf2 nuclear accumulation. Dose-dependent
accumulation of Nrf2 in nucleus and increasing Nrf2 target gene expression occurs in Nrf2-
knockout, Keap1-knockdown and liver-specific Keap1 knockout mice [4]. The effects of
Nrf2 and Keap1 knockout/knockdown are well described in models of liver injury caused by
acetaminophen, diquat, cadmium, alcohol, or oxidative stress [5-10]. But the effects are
largely undescribed for hyperlipidemia and tissues important to metabolic syndrome, such as
adipose tissue and skeletal muscle (SKM).
Central obesity is a major hallmark of metabolic syndrome. Multiple nuclear receptors
influence stem cell differentiation to adipocytes and adipocyte maturation. For example,
multiple CCAAT-enhancer-binding protein isoforms (Cebpα and Cebpβ) are required at
various stages of adipocyte differentiation [11]. Peroxisome proliferator-activated receptor-
gamma (Ppar-γ) is known as a key regulator of fat synthesis, which regulates additional
genes that contribute to lipid storage, such as Fatty acid binding protein 4 (Fabp4), Cluster
of Differentiation 36 (Cd36, fatty acid translocase), Lipoprotein lipase (Lpl) and steroyl
CoA desaturase (Scd1) [12]. Acetyl CoA carboxylase 1 (Acc1) catalyzes formation of
malonyl CoA, which is a vital substrate for fatty acid biosynthesis [13]. Malonyl CoA also
inhibits β-oxidation of fatty acids. Phosphorylated Acc1 (pAcc1) is an inactive form of
Acc1. Fatty acid synthase (Fas) uses precursors like acetyl CoA and malonyl CoA to
synthesize long chain saturated fatty acids. Steroyl CoA desaturase 1 (Scd1) catalyzes
synthesis of unsaturated fatty acids from saturated fatty acids [13]. Lipoprotein lipase (Lpl)
breaks down triglycerides (TG) from lipoproteins to release free fatty acids [14]. In
summary, all of the abovementioned enzymes/ enzyme complexes are responsible for fatty
acid levels in the tissues as well as serum.
Adipocytes function to not only store fat, but also produce and secrete ‘adipocytokines’ that
include bioactive products such as inflammatory mediators (e.g. Interleukin-6, IL-6;
monocyte chemoattractant protein, Mcp1; tumor necrosis factor, Tnf), which are considered
to be a cause of insulin resistance and non-alcoholic fatty liver disease [15, 16]. Obesity
increases the presence of M1 pro-inflammatory macrophages in adipose tissue, increases
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secretion of pro-inflammatory cytokines, and increases M1 hepatic macrophages and
inflammation [17].
In adipose tissue, Nrf2 binds to an ARE present in the Ppar-γ promoter to promote adipocyte
differentiation [18]. Nrf2 knockout mice were protected against hepatic steatosis induced by
high fat diet (HFD) feeding [19], indicating that Nrf2 presence is needed for hepatic lipid
accumulation. Huang et al. (2010) illustrated that targeted Nrf2 deletion protects against
high fat diet induced steatosis through dowregulation of Cd36, Sterol regulatory element
binding protein 1c (Srebp-1c), Fas, Ppar-γ expression, and upregulation of Small
heterodimeric partner (Shp) -dependent pathways. Moreover, OB-Keap1KD exhibit
increased hepatic steatosis compared to OB mice [20]. In contrast, Kay et al. (2011) report
inverse that NRF2 and SREBP1c are inversely regulated in human livers with steatosis [21].
Because hepatic steatosis is a manifestation of metabolic syndrome, better understanding of
Nrf2 function in hepatic lipid accumulation in the face of dyslipidemia is needed.
The study herein describes the effect of chronic HFD-feeding on markers of metabolic
syndrome including 1) WAT mass and hepatic steatosis, 2) glucose clearance, and 3) WAT
and liver inflammation in C57BL/6 and Keap1-knockdown mice. Overall, Keap1-KD mice
exhibited increased markers of metabolic syndrome with long-term HFD feeding.
MATERIALS AND METHODS
Animals
Mice with Keap1 knockdown (Keap1-KD), congenic to C57BL/6 background were
generously shared by Dr. Curtis Klaassen (Kansas University Medical Center, Kansas City,
KS) and Dr. Masayuki Yamamoto (Tohoku University Graduate School of Medicine,
Sendai, Japan). The mice are described in multiple publications from Yamamoto and
Klaassen [22-24]. Male age-matched C57BL/6 and Keap1-KD mice were bred in-house and
fed diet containing either 10% kcal fat (LFD, Research Diets Inc, D12450B) or 60% kcal fat
(HFD, Research Diets Inc, D12492) starting at wean (3 weeks) (n=4 or 5 per group). Body
weights were measured every week starting from six weeks of age (3 weeks on diet). At the
age of 27 weeks, blood, liver, SKM, and WAT, and brown adipose tissue were collected.
The study herein was reviewed and approved by the University of Rhode Island Institutional
Animal Care and Use Committee (IACUC protocol # AN11-11-007) and the number of
mice used was based upon required power analysis.
Glucose tolerance test (GTT)
The GTT was performed on the mice at 25 weeks of age. Mice were fasted for 8 hours
overnight and were administered a bolus dose of glucose solution by oral gavage (1g/kg
body weight). The blood glucose levels were recorded at 0, 15, 30, 60, and 120 minutes after
glucose administration from tail blood using a Contour® glucometer (Bayer HealthCare
LLC, Tarrytown, NY).
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Hepatic triglyceride (TG) quantification
Total lipids were extracted from liver tissue by methanol-chloroform extraction according to
[25] and TGs were quantified using a kit from Pointe Scientific Inc (Canton, MI) according
to manufacturer’s protocol.
Hematoxylin and Eosin staining
After harvesting, a small section of liver tissue from the central lobe of the liver, WAT, or
brown adipose tissue was stored in formaldehyde for 24 hour and then in 75 % ethanol until
further processing for paraffin embedding. Paraffin-embedded tissues were cut to
approximately 5 m sections, and then stained with hematoxylin and eosin.
Oil red O staining
Frozen liver tissues were sectioned (5 M) on Vibratome UltraPro 5000 Cryostat® (GMI
Inc., Ramsey, MN). Sections were then fixed in 10% formalin for 5 min and slides were
washed in water. Then slides were immersed in 60% isopropanol five times and incubated in
Oil red O solution for 15 min. The slides were immersed in fresh 60% isopropanol solution
twice and then counter stained with hematoxylin. Excess hematoxylin was removed with a
water wash and the slides were covered using Vectamount aqueous solution and coverslips.
Neutrophil staining
Neutrophil staining of paraffin embedded liver and WAT sections was performed as
described in [26]. Briefly, 4μM sections on adhesive slides were dried, de-paraffinized and
placed in TBS of pH 7.5 for 5 min. Enzyme Induced Epitope Retrieval (20 minutes in 0.04%
Pepsin in 0.2NHCl) followed by subsequent rinses and blocking for endogenous peroxidase
using 3% Hydrogen Peroxide/Methanol bath (1:4 ratio) for 20 minutes followed by rinses
with water. Pretreatment was followed by blocking with rabbit serum and endogenous
Biotin blocking by incubation in Avidin D (Vector) and d-Biotin (SigmaAldrich, St.Louis,
MO) for 15 minutes. Slides were then incubated with primary antibodies diluted in normal
diluent for 1 hr (Neutrophil-NIMP R14 from Santa Cruz Biotech, CA). Biotinylated
secondary antibody incubation was followed by RTU VectaStain Elite ABC Reagent
(Vector Laboratories, Burlingame, CA), reaction developed by Nova Red followed by
counterstain Gill 2 Hematoxylin (Richard Allen, Kalamazoo, MI). The slides were then
rinsed, dried and permanently mounted with Flotex media.
Serum cytokine analysis
Serum Mcp1 levels were measured using Mouse Mcp1 ELISA Max kit (# 432704) from
Biolegend (San Diego, CA) according to the manufacturer’s protocol.
Total RNA extraction and mRNA quantification
Total RNA from liver, WAT and SKM was isolated by phenol-chloroform extraction using
RNA Bee reagent (Tel-Test Inc, Friendswood, TX) according to the manufacturer’s
protocol. RNA concentration was quantified by absorbance at 260 nm using a
spectrophotometer (Nanodrop ND1000, Thermo Fisher Scientific, Waltham, MA) and the
samples were diluted to 1 g/ L. Formaldehyde–agarose gel electrophoresis followed by UV
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illumination was used to visualize RNA and confirm integrity. Messenger RNA was
quantified by QuantiGene (QGP) Plex 2.0 or 1.0 assay.
For QGP 2.0 assay, all the reagents including capture buffer, magnetic capture beads,
preamplifier, amplifier, label probe, diluents, and substrate solution were provided in the kit
(Affymetrix, Santa Clara, CA). On day one, 1000ng of RNA was incubated with capture
beads and target specific probe set mixture for hybridization for 18-22 hrs. After
hybridization, the beads were washed on BioPlex Pro wash station I (BioRad, Hercules CA),
using magnetic plate washer. Then beads were hybridized with preamplifier, amplifier and
label probe for 1 hr each and with washings in-between with wash buffer. After incubation
with label probe, the beads were washed and incubated with streptavidin phycoerythrin
(SAPE) for 30 min. The beads were then washed with SAPE washing buffer and re-
suspended in it for reading on Bioplex microplate luminometer. The data was processed by
BioPlex Manager software 5.0. Target gene expression was normalized to Hprt1 expression.
The QGP 1.0 assay (also referred to as the Branched DNA Signal Amplification assay)
procedure has been described in detail elsewhere [27, 28]. All reagents for analysis
including lysis buffer, amplifier/label probe diluent and substrate solution were supplied in
the QuantiGene 1.0 assay kit (Panomics, Fremont, CA). Oligonucleotides were first
dissolved in 10 mM Tris-HCl (pH 8.0) containing 1 mM EDTA and were diluted 1:100 in
lysis buffer before use [29]. On day one, total RNA samples (10 μg, 1 μg/μL) were added to
wells containing 50 μL of capture hybridization buffer and 50 μL of diluted probe set. The
RNA was allowed to hybridize overnight with probe set at 53°C. On day two, subsequent
hybridization steps were followed as mentioned in manufacturer’s protocol, and
luminescence was measured with a GloRunnerTM microplate luminometer interfaced with
GloRunner DXL Software (Turner Biosystems, Sunnywale, CA). The luminescence for each
well was reported as relative light units (RLU) per 10 μg of total RNA. The raw data was
used to plot graphs for mRNA expression.
Total protein extraction and western blotting
About 50mg of liver tissue was homogenized in 1mL RIPA buffer using Dounce
homogenizer. The homogenate was centrifuged at 12000 rpm for 10 minutes, and the
supernatant was stored at −80°C for future use as a total protein fraction. The extract was
quantified for protein content by Lowry assay. Relative protein expression was evaluated by
western blot. Fifty microgram of total protein extract pre-mixed with Laemmli was loaded
on polyacrylamide gel (4% stacking, 12% resolving), transferred on PVDF membrane,
stained with different antibodies enlisted in supplementary table ST1. The membrane was
then incubated with ECL+ (GE Healthcare, Waukesha, WI) and chemiluminescence was
exposed to X-ray film. The resulting bands on autoradiography films were evaluated using
Quantity One® software from BioRad.
Statistical Analysis
Groups were analyzed by a one-way ANOVA followed by a Duncan’s Multiple Range post
hoc test and planned comparison between C57BL/6 and Keap1-KD groups were performed
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among HFD groups after performing the one-way ANOVA. Different letters indicate
statistically significant difference between the groups (p<0.05).
RESULTS
Effect of Keap1-KD on body, WAT, and liver weight and food consumption with long-term
HFD feeding
Figure 1A depicts body weight change over 24 weeks. There was no significant difference in
body weight between C57BL/6 and Keap1-KD mice fed the LFD. Keap1-KD mice fed HFD
had significantly higher body weight between weeks 17-24, compared to C57BL/6 mice fed
HFD. At weeks 8 and 9, the HFD did not increase body weight in Keap1-KD mice as much
as C57BL/6 mice. However, around 11th week feeding the HFD, the trends in body weight
gain appeared to reverse, with Keap1-KD mice having body weight higher than C57BL/6
mice. Food consumption (Fig. 1B) for the LFD groups stayed within the range of 15-20 g/
week per mouse for entire duration of the study. For HFD fed mice, it was noted that food
consumption appeared slightly higher in C57BL/6, as compared to Keap1-KD mice
throughout the study (no statistical significance). Blood glucose levels of the mice
throughout the course of study were observed to remain in the range of 100 to 200 mg/dL,
with no significant difference between any of the groups (Supplementary figure SF1). HFD
feeding increased WAT weight (Fig 1C) significantly higher in Keap1-KD compared to
C57BL/6 mice. At 24 weeks of feeding the LFD or HFD, Keap1-KD mice also had an
increased liver-to-body weight ratio as compared to C57BL/6 mice on the respective diet.
Brown adipose tissue of Keap1-KD mice fed HFD displayed hypertrophy in hematoxylin
and eosin stained sections as compared to C57BL/6 mice (Supplementary figure SF2).
Keap1 knockdown increases liver steatosis with chronic HFD feeding
As depicted in Fig. 2A, the HFD increased lipid accumulation in the liver compared to the
LFD. Keap1-KD mice fed the HFD had a higher degree of steatosis compared to C57BL/6
mice, as seen with hematoxylin and eosin staining. Oil red O staining of neutral lipids also
revealed that the HFD significantly increased hepatic steatosis, with higher levels being
observed in Keap1-KD mice (Fig. 2B). Correspondingly, the HFD increased hepatic
triglycerides (Fig. 2C); with significantly higher TG levels being detected in livers of
Keap1-KD mice compared to C57BL/6 mice.
Keap1 knockdown increases lipogenic gene and protein expression in liver
Fig. 3A depicts lipogenic gene expression on mRNA level in liver. Ppar-γ and Cd36 mRNA
expression increased significantly in Keap1-KD mice as compared to C57BL/6 mice, in both
LFD and HFD fed groups. Fabp4 mRNA expression increased in Keap1-KD mice fed HFD
compared to C57BL/6 mice. Lpl mRNA expression was higher in C57BL/6 mice fed LFD
compared to all other groups, whereas Scd1 expression remained unchanged between all the
groups. Fig. 3B and 3C depicts increased mRNA expression of Nrf2 and its target genes,
NADPH quinone oxidoreductase (Nqo1) and glutamate cysteine ligase, catalytic subunit
(Gclc) in livers and WAT of Keap1-KD mice. Expression of Nrf2 and its target genes was
quantified in order to characterize the Keap1-KD model. Protein expression of similar
adipogenic targets also tended to increase livers of Keap1-KD mice fed HFD (Fig. 4). HFD
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slightly increased Pparγ protein expression in Keap1-KD mice, however the change did not
reach statistical significance. Phosphorylated acetyl CoA carboxylase 1 (pAcc1), Acc1, and
Scd1 protein levels were increased in Keap1-KD mice fed HFD compared to C57BL/6 mice.
Fatty acid synthase (Fas) protein expression was equivalent among all groups; however,
HFD groups displayed an increasing trend in expression (not statistical), as compared to
LFD.
Keap1-KD increases liver and WAT tissue inflammation
Neutrophil staining of paraffin-embedded liver sections revealed increased infiltration in the
HFD fed mice, with even more neutrophils in Keap1-KD mice fed HFD (Fig. 5A). Serum
levels of Mcp1 tended to increase in Keap1-KD mice fed either LFD or HFD, but this did
not achieve statistical significance (Fig. 5B). Quantification of relative pro-inflammatory
cytokine mRNA expression in liver tissue supported the histological staining. Mcp1 mRNA
expression in liver was higher in Keap1-KD compared to C57BL/6 mice fed HFD (Fig. 5C).
Tnf mRNA expression remained constant between C57BL/6 and Keap1-KD mice fed same
diet.
Chronic feeding of the HFD caused increased cellularity in WAT (Fig. 6A), which is often
associated with presence of neutrophils and macrophages [30]. After chronic HFD feeding,
WAT from Keap1 mice had increased cellularity and inflammation compared to C57BL/6
mice, as determined by histopathological analysis. Messenger RNA levels of
proinflammatory macrophage M1-marker Tnf was elevated in WAT of Keap1-KD mice fed
HFD as compared to C57BL/6 mice fed HFD (Fig. 6B). Mcp1 and Cd11c mRNA levels
were higher in HFD fed groups, but there was no significant difference between the
C57BL/6 and Keap1-KD mice.
Keap1-KD alters glucose clearance and insulin signaling protein expression in SKM
After 23 weeks of feeding the LFD or HFD, mice were subjected to a glucose tolerance test
(GTT), as a measure of diabetes and insulin resistance. No differences in glucose levels after
glucose administration were detected between C57BL/6 or Keap1-KD mice fed the LFD.
Mice fed the HFD had higher blood glucose levels compared those fed the LFD. After 15,
30 and 60 min of glucose administration, the blood glucose levels of Keap1-KD mice fed
HFD were about 1.5 fold higher compared to C57BL/6 mice fed the HFD (Fig. 7A). Area
under the curve (AUC) for GTT also demonstrated that blood glucose levels remained
significantly high in Keap1-KD mice fed HFD as compared to C57BL/6 mice fed HFD (Fig.
7B) for the duration of 2 hrs.
In accordance with the GTT, the expression of insulin signaling target insulin receptor
substrate 1 (Irs1) was also down regulated in SKM. In HFD fed mice, Keap1-KD mice had
decreased mRNA expression of Irs1 compared to C57BL/6 mice (Fig. 7C). However, Glut4
mRNA and protein expression was similar between all the groups, as determined by QGP
2.0 assay and western blot respectively (Fig. 7C and 7D).
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DISCUSSION
Metabolic syndrome is considered to be a manifestation of obesity, characterized by
increased central abdominal mass, dyslipidemia (e.g. increased serum triglycerides),
increased hepatic steatosis and markers of systemic inflammation, and dysregulation of
glucose tolerance [31]. To date, no study has evaluated the effect of Keap1 knockdown on
development of metabolic syndrome. The present study demonstrates that Keap1
knockdown increased some markers of metabolic syndrome after long term HFD feeding.
Along with increased body weight and WAT mass, Keap1-KD mice fed a HFD displayed
increased hepatic and white adipose markers of inflammation, hepatic steatosis, increased
adipose cellularity, and altered glucose homeostasis. Taken together, these data suggest that
Keap1 knockdown, and perhaps persistent Nrf2 activation, are associated with increased
metabolic syndrome risk with HFD challenge.
The present data indicate that Keap1-KD mice had significantly higher body weight and
adipose tissue mass compared to C57BL/6 mice with chronic long-term HFD feeding, which
are in line with other published findings. Pi et al. described adipose tissue changes in
Nrf2−/− mice [18]. The body weight of Nrf2−/− mice was significantly lower than wild type
mice fed an ad libitum diet. Abdominal fat pad mass, and adipocyte size was also
significantly smaller in mice with Nrf2−/− mice. Nrf2−/− mice were also resistant to diet-
induced obesity, when fed 41% kCal fat diet for 12 weeks after weaning. Also, adipocytes
derived from Nrf2−/− mouse embryonic fibroblasts accumulated less lipids compared to
those derived from Nrf2+/+ mouse embryonic fibroblasts [18]. Another study by Huang et
al. also demonstrated that deletion of Nrf2 (Nrf2−/−) in mice resulted in reduced body
weight in Nrf2−/− mice fed a HFD for approximately three months. These mice also had
lower hepatic TG content when challenged with HFD, compared to Nrf2+/+ mice [19].
Nrf2−/− mice displayed better insulin sensitivity, measured by glucose tolerance, as
compared to wild type mice fed HFD for 180 days [32]. The data herein also demonstrate
that Keap1-KD mice display increased hepatic steatosis compared to C57BL/6 mice. It was
observed that the HFD increased hepatic lipid accumulation along with increased lipogenic
gene and protein expression (e.g. Fabp4 mRNA, Cd36 mRNA, pAcc1 protein), which was
augmented in Keap1-KD mice. This observation is consistent with a report by Huang et al.,
2010, which reported decreased hepatic lipid accumulation in livers of Nrf2−/− mice after
long term HFD feeding. An interesting change in body weights was noted in the HFD fed
groups. Up to about 8-9 weeks of feeding the HFD, C57BL/6 mice appeared to have
significantly higher body weight as compared to Keap1-KD mice, which is consistent with
our previous observation [33]. However, this difference diminished at about 11 weeks of
feeding HFD and then by 19 weeks of HFD feeding, Keap1-KD mice weighed significantly
higher than C57BL/6. Food consumption did not significantly differ between genotypes,
suggesting the observed increase in metabolic syndrome markers in Keap1-KD mice are
related to lipid metabolism and not appetite. Zhang et al. recently reported no alterations in
body and liver weights in Keap1-KD mice fed 40% kCal fat diet for 12 weeks [34]. The
results herein differ from Zhang et al., perhaps because our study used 60% kCal fat diet and
was significantly longer in duration. However, our results are consistent with Zhang et al.
and Xu et al., when duration of feeding is considered. For example, in the present study,
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body weights were similar between C57BL/6 and Keap1-KD mice after 12 weeks of HFD
feeding (15 weeks of age), which is consistent with Zhang et al. Also, our group reported
that Keap1 knockdown protected against HFD-increased weight gain [33], which on a
cursory review seems inconsistent with the present study. Again, when one evaluates the
response of Keap1-KD mice with regard to duration on a HFD, the present data are also
consistent with Xu et al. In Xu et al., HFD feeding started at 9 weeks of age for 5 weeks in
duration. In the present study, Keap1-KD mice had lower body weights compared to
C57BL/6 mice on the HFD after 5 weeks of feeding, consistent with Xu et al [33]. It appears
that short term versus long term HFD in Keap1-KD produce different outcomes with regard
to body weight.
In contrast to the present finding, others report that activation of Nrf2 is protective against
HFD-induced obesity and steatosis, but this is typically reported in conjunction with
pharmacological Nrf2 activating compounds. Chemical activators of Nrf2 including,
oltipraz, CDDO-imidazole, and sulforaphane in separate studies protected mice against
obesity and steatosis [21, 35, 36]. When administered with oltipraz, HFD feeding did not
have obesogenic effects on mice for up to 28 weeks. Body weight, liver weight and adipose
tissue weight gain induced by HFD feeding was prevented with oltipraz co-administration
C57BL/6J mice [35]. Similarly, the synthetic triterpenoid CDDO-imidazole also prevented
weight gain in mice fed HFD for 3 and 13 weeks [36]. In an experiment with hepatocytes,
Nrf2 activator sulforaphane suppressed Liver × receptor (Lxr) dependent steatosis [21]. It is
not clear why pharmacological Nrf2 activators impact HFD feeding differently compared to
genetic models of Nrf2 manipulation, but perhaps other receptor systems (e.g. Constitutive
Androstane Receptor and Pregnane × receptor) might also be activated [24, 37]. One must
also consider the absorption, metabolism, and disposition of the chemical inducers being
administered in comparison to a genetically manipulated mouse model that has whole body
Keap1 knockdown.
The present study also demonstrated that constitutive Nrf2 activation altered glucose
homeostasis. As GTT is an indicator of sensitivity of cells to respond to insulin action,
ability of pancreas to produce insulin and ability of liver to store glucose, expression of
insulin responsive targets in the SKM could partially explain the reason for the insulin
intolerance. SKM is one of the major glucose utilizing tissues in the body and Glut4 is a
predominant glucose transporter responsible for insulin stimulated glucose uptake in SKM
[38]. Keap1-KD mice fed the HFD had unaltered mRNA and total protein expression of
Glut4. However, the mRNA expression of Irs1 mRNA, a protein involved in molecular basis
for action of insulin [39], was decreased in Keap1-KD mice fed the HFD, supporting data
obtained from GTT in Keap1-KD mice. It is possible that glucose uptake in skeletal muscles
was not altered in Keap1-KD mice fed HFD due to total Glut4 protein expression. Glut4
translocation to the membrane or defects in Irs-1 or Akt phosphorylation in response to
glucose or insulin could also be potentially considered. The Keap1-KD mice fed HFD
demonstrate a disturbance in glucose homeostasis with glucose challenge, which does
suggest a potential for development of insulin resistance.
Adipocytes act as endocrine cells, secreting variety of adipocytokines including leptin,
adiponectin, as well as interleukins [40]. In genetic and diet-induced obese mouse models,
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the expression of inflammation and macrophage markers was increased in WAT of obese
compared non-obese mice [41]. Inflammation is one of the most critical etiological factors
in development of insulin resistance [42, 43]. The current data illustrate that the Keap1-KD
mice fed the HFD had increased measures of inflammation in WAT and liver. Both WAT
and liver had increased inflammation, as noted by increased cellularity (WAT) and
neutrophil staining (NIMP R14, Liver). HFD fed Keap1-KD mice were found to have higher
levels of cytokines levels in serum and higher expression of cytokine mRNA in liver, as
compared to C57 mice fed HFD. Expression of pro-inflammatory M1 macrophage markers
was higher in Keap1-KD mice fed HFD, indicating possible role of long term Nrf2
activation in inflammation.
The reason why increased Nrf2 activation might promote lipogenesis and inflammation with
HFD feeding is intriguing. It remains to be determined whether lipid accumulation preceded
inflammation, but it is likely. Nrf2 has been shown to be a positive regulator of the mouse
Ppar-γ promoter, increase Ppar-γ expression, and promote adipogenesis [18], with a similar
mechanism occurring in liver [33]. Thus, the persistent Nrf2 activation in liver appeared to
promote lipid accumulation via upstream Ppar-γ activation. Perhaps an increased
biotransformation due increased Nrf2 activity resulted in increased lipids that caused tissue
injury and inflammation. The data clearly demonstrate increased inflammation in liver and
WAT, yet an underlying mechanism for the increased inflammation remains to be
determined.
Along with Nrf2, Keap1 is also implicated to interact with Nrf1 [44]. Nrf1, like Nrf2, also
belongs to basic leucine zipper family of transcription factors. It plays a role in combating
oxidative stress by increasing glutathione levels [45]. However, a review by Biswas and
Chan mentioned that functions of Nrf1 and Nrf2 are not completely redundant [46]. Nrf1
also plays role in regulating inflammatory targets including inducible nitric oxide synthase
[46]. Although Keap1 has much lower affinity for Nrf1 compared to Nrf2 [47], it is still
possible that Keap1-KD mice would have slightly increased levels of Nrf1. The effect of
Nrf1 on obesity/ diabetes is a relatively under-investigated area.
Our results herein are also of relevance to the study of obesogenic compounds, as the Nrf2
pathway is inducible and functional in adipose tissue and skeletal muscle [33] and Nrf2 is
activated by multiple environmental chemicals [48]. Thus, it is of potential interest to better
understand whether Nrf2 activation via environmental chemical could intersect with
obesogenic or pro-metabolic syndrome effects via environmental chemical exposure [49]. In
summary, the data herein demonstrate that Keap1-KD mice, which have Keap1 knocked
down and constitutive Nrf2 activation, were susceptible to increased markers of metabolic
syndrome, such as diet-induced obesity, hepatic steatosis, and glucose intolerance
concomitant with increased in inflammation in liver and adipose tissue, after long-term HFD
feeding. Overall, this study suggests that Nrf2 has a role beyond combating oxidative stress
and further investigation is needed to better understand Nrf2-Keap1 interactions with
chronic HFD challenge.
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HIGHLIGHTS
• Keap1 knockdown increased body weight, adipose tissue mass, and hepatic steatosis
after 24 weeks of high fat diet feeding
• Keap1 knockdown altered short-term glucose homeostasis after 24 weeks of high fat
diet feeding
• Keap1 knockdown increased markers of metabolic syndrome induced by high fat diet
feeding
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Figure 1. Body, liver and WAT weight and adipocyte size of C57BL/6 and Keap1-KD mice fed a
10% kCal low fat diet (LFD) or 60% kCal high fat diet (HFD)
A) Body weights (starting from age 6 weeks) and B) food consumption of C57BL/6 (C57)
and Keap1-KD mice fed a LFD or HFD from weaning age to 27 weeks (starting at age 6
weeks). C) Abdominal adipose tissue weight and liver to body weight ratio. Differences
between the groups were analyzed by a one-way ANOVA followed by a Duncan’s post hoc
test. Different letters indicate statistically significant difference between the groups
(p<0.05). For example, letter “a” is significantly different from “b”, but not different from
“a”. Also, “a” is significantly different from “b,c” but not different from “a,b”.
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Figure 2. Hepatic lipid accumulation and triglyceride (TG) content in C57BL/6 (C57) and
Keap1-KD mice fed a 10% kCal low fat diet (LFD) or 60% kCal high fat diet (HFD)
A) Hematoxylin and eosin staining of formaldehyde fixed paraffin embedded liver tissues
(200X magnification). B) Oil red O staining of liver sections. Frozen liver tissues were
sectioned in 5 m sections, stained with Oil red O, and counter stained with hematoxylin
(200X magnification). C) Hepatic TG content. Lipids were extracted using a methanol-
chloroform based protocol and the resulting TG content was assayed using kit from Pointe
Scientific (Canton, MI). Differences between the groups were analyzed by a one-way
ANOVA followed by a Duncan’s post hoc test. Different letters indicate statistically
significant difference between the groups (p<0.05).
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Figure 3. Lipogenic, Nrf2, and Nrf2 target gene expression in livers and white adipose tissue
(WAT) of C57BL/6 (C57) and Keap1-KD mice fed a 10% kCal low fat diet (LFD) or 60% kCal
high fat diet (HFD)
Total RNA was extracted from the livers by phenol-chloroform extraction and mRNA was
quantified using Quantigene Plex 2.0 or Branched DNA Signal Amplification assay
(Affymetrix, Santa Clara, CA). A) Peroxisome proliferator activated receptor (Ppar-γ),
Steroyl CoA desaturase (Scd1), Fatty acid binding protein 4 (Fabp4), Lipoprotein lipase
(Lpl), and Cluster of differentiation (Cd36) mRNA expression. B) Nrf2, NADPH:quinone
oxidoreductase (Nqo1), glutamate cysteine ligase (Gclc) mRNA expression in liver. C) Nrf2
and Nqo1 mRNA expression in WAT. Differences between the groups were analyzed by a
one-way ANOVA followed by a Duncan’s post hoc test. Different letters indicate
statistically significant difference between the groups (p<0.05). For example, letter “a” is
significantly different from “b”, but not different from “a”. Also, “a” is significantly
different from “b,c” but not different from “a,b”.
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Figure 4. Protein expression of lipogenic enzymes in livers of C57BL/6 (C57) and Keap1-KD
mice fed a 10% kCal low fat diet (LFD) or 60% kCal high fat diet (HFD)
A) Western blots for lipogenic enzymes in liver. Total protein extracts were separated on
polyacrylamide gel, immunoblotted, and chemiluminescence was captured on X-ray films.
B) Western blot quantification. The resulting blots obtained were evaluated using Quantity
One® software (Biorad, Hercules, CA) and band density is plotted as percent of C57BL/6
fed LFD. Differences between the groups were analyzed by a one-way ANOVA followed by
a Duncan’s post hoc test. Different letters indicate statistically significant difference
between the groups (p<0.05).
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Figure 5. Inflammatory markers in liver and serum of C57BL/6 (C57) and Keap1-KD mice fed a
10% kCal low fat diet (LFD) or 60% kCal high fat diet (HFD)
A) Neutrophil (NIMP R14) staining of paraffin embedded liver sections. Images displayed
in 200X magnification. B) Serum cytokine Monocyte chemoattractant protein 1 (Mcp1)
levels C) mRNA expression of inflammatory cytokine markers Mcp1, Tumor necrosis factor
(Tnf) and Cd11c in liver. Total RNA was extracted from liver tissue by phenol-chloroform
extraction and mRNA was quantified using Quantigene Plex 2.0 assay (Affymetrix, Santa
Clara, CA). by a Duncan’s post hoc test. Different letters indicate statistically significant
difference between the groups (p<0.05).
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Figure 6. White adipose tissue (WAT) cellularity and inflammation in C57BL/6 (C57) and
Keap1-KD mice fed a 10% kCal low fat diet (LFD) or 60% kCal high fat diet (HFD)
A) Hematoxylin and eosin stained sections of paraffin embedded WAT. Images displayed in
200X magnification. B) Messenger RNA expression of proinflammatory macrophage
markers monocyte chemoattractant protein 1 (Mcp1), tumor necrosis factor (Tnf) and Cd11c
in WAT. Differences between the groups were analyzed by a one-way ANOVA followed by
a Duncan’s post hoc test. Different letters indicate statistically significant difference
between the groups (p<0.05).
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Figure 7. Glucose tolerance test (GTT) and expression of insulin signaling molecules in skeletal
muscle (SKM) of C57BL/6 (C57) and Keap1-KD mice fed a 10% kCal low fat diet (LFD) or 60%
kCal high fat diet (HFD)
A) GTT after 23 weeks of LFD or HFD treatment. Mice were fasted overnight and
challenged with an oral glucose bolus (1g/kg). Blood glucose levels were recorded at 0, 15,
30, 60, and 120-minute time points using Contour® glucose meter (Bayer HealthCare LLC,
Tarrytown, NY). *Represents statistically significant difference of glucose levels between
C57BL/6 and Keap1-KD mice fed same diet. B) Area under the curve (AUC) plotted for the
GTT. C) Messenger RNA expression of insulin receptor substrate 1 (Irs1) and glucose
transporter Glut4 in SKM. Total RNA was extracted from liver tissue by phenol-chloroform
extraction and mRNA was quantified using Quantigene Plex 2.0 assay (Affymetrix, Santa
Clara, CA). For parts Differences between the groups were analyzed by a one-way ANOVA
followed by a Duncan’s post hoc test. Different letters indicate statistically significant
difference between the groups (p<0.05). For example, letter “a” is significantly different
from “b”, but not different from “a”. Also, “a” is significantly different from “b,c” but not
different from “a,b”. D) Protein expression of Glut4 from skeletal muscle of C57BL/6 and
Keap1-KD mice fed LFD and HFD by western blot (n=2 per group).
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